Panacea Global Inc Stock

PANG

US6981031080

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

Press Releases : Panacea Global Inc

15-05-27

Panacea Global : Attains the Option to Purchase Majority Rights to the HAAH-Based Blood Test for the U.S. Market

More press releases

Managers and Directors : Panacea Global Inc

Manager	Title	Age	Since
Yuri Lawryshyn CEO	Chief Executive Officer	60	2016-06-16
David Sohi DFI	Director of Finance/CFO	-	2016-06-16

Director	Title	Age	Since
Adel Hanna BRD	Director/Board Member	-	-
Nour Nasr BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PANACEA GLOBAL INC	-.--%	-.--%	-	-	0
LONZA GROUP AG	-2.54%	-2.84%	-1.77%	+14.72%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+523.39%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+21.22%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+74.90%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+47.12%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+123.04%	16.5B
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+13.91%	+31.45%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.22%	13.77B
Average	-0.83%	+0.53%	+74.05%	+109.63%	30.55B
Weighted average by Cap.	-1.03%	+0.11%	+89.42%	+127.93%

See all sector performances

Panacea Global, Inc. is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis and monitoring the recurrence of cancer. The Company's product is a blood test that can measure the blood level of Human Aspartyl (Asparaginyl) B-Hydroxylase (HAAH). Its HAAH (a cancer biomarker) is an enzyme, which is over expressed in cancer cells. This test is recommended for men and women over 50 years of age with a history of smoking cigarettes. Its HAAH Blood Test can help the early diagnosis of prostate cancer. Its HAAH Blood Test provides the physician with additional information about the likelihood that a man with an abnormally high prostate-specific antigen (PSA) value, with or without an abnormal digital rectal examination (DRE), may have prostate cancer. Its HAAH Blood Test provides information to differentiate prostate cancer from benign conditions and to help guide patient management.

Employees

Sector

Biotechnology & Medical Research

More about the company